Adenoma Clinical Trial
Official title:
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial
Verified date | June 2024 |
Source | St. Olavs Hospital |
Contact | Stine L Fougner, md phd |
stine.fougner[@]ntnu.no | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Due to lack of hormone overproduction in non-functioning pituitary adenomas (NFPAs), only the symptomatic adenomas or large adenomas with proven growth and risk for symptoms in near future will undergo pituitary surgery. The remaining adenomas are monitored regularly. Operation of these large adenomas will rarely remove all tumour tissue, and there is also a risk of worsening of pituitary function. Often, adenomas with the highest growth potential are operated several times and some also need radiation therapy, providing additional risk for pituitary failure. Unlike some of the hormone-producing adenomas, there is no established pharmacological treatment for NFPAs. However, there are a few non-randomized studies suggesting that treatment with dopamine agonists may slow growth, and also induce tumour shrinkage. At present, cabergoline is the dopamine agonist most widely used in the treatment of pituitary adenomas secreting prolactin. Aim is to study the effect of medical treatment with cabergoline in non-functioning pituitary adenomas on the change in tumour volume.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 2027 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - A previously untreated non-functioning pituitary macroadenoma (largest diameter = 10 mm) with either demonstrated growth on repeated MRI scans or = 2 mm distance to chiasma opticum, or: - a residual non-functioning pituitary adenoma after surgery (largest diameter = 5 mm) that is either extrasellar and/or with documented growth after surgical treatment of a non-functioning pituitary macroadenoma Exclusion Criteria: - Clear indication for surgery at the time of inclusion - Previous radiation therapy - Pituitary surgery the last 6 months - Previous apoplexy/bleeding in the adenoma - Pregnancy or lactation - Contraindications for cabergoline treatment (Known cardiac valvular disease, known pulmonal, pericardial or retroperitoneal fibrosis, clinical significant liver insufficiency, use of medications that interact with cabergoline - unfit to participate due to any other reason |
Country | Name | City | State |
---|---|---|---|
Norway | Department of Endocrinology, Akershus University hospital | Oslo | |
Norway | Department of Endocrinology, St. Olavs Hospital | Trondheim | |
Sweden | Sahlgrenska University Hospital | Gøteborg |
Lead Sponsor | Collaborator |
---|---|
St. Olavs Hospital | Norwegian University of Science and Technology |
Norway, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in tumour volume during the main study of two years | This includes the percentage and absolute change in tumour volume, but also the number of patients with significant tumour shrinkage or tumour growth (defined by = 10 % or = 2 mm shrinkage/growth in at least one dimension) | 2 years | |
Secondary | need for surgical and/or radiation treatment | up till 2 years | ||
Secondary | changed pituitary function | measured by analysis of blood tests, basal and stimulation tests | up till 2 years | |
Secondary | change in tumour's distance to chiasma opticum in mm | as measured by analysis of MRI images | up till 2 years | |
Secondary | development of cardiac valvulopathy | as measured by analysis of echo cardiography | up till 2 years | |
Secondary | impulse control disorder | as measured by questionnaire visual files: clinical evaluation by ophthalmologist and perimetry | up till 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT02545699 -
Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy
|
N/A | |
Completed |
NCT01802008 -
Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times
|
N/A | |
Recruiting |
NCT01211132 -
Cap Assisted Colonoscopy for the Detection of Colon Polyps
|
N/A | |
Completed |
NCT04287335 -
Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China
|
||
Not yet recruiting |
NCT06398418 -
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05362344 -
Colorectal Cancer Screening in Cystic Fibrosis
|
||
Completed |
NCT03268200 -
The Effect of Segmental Re-examination of Colon for Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT04591145 -
Multi-center Validation of a Deep Learning Based Bowel Preparation Evaluation System
|
||
Completed |
NCT02978664 -
The Impact of Distraction on Adenoma Detection Rate
|
N/A | |
Completed |
NCT00018551 -
Chemoprevention With Folic Acid
|
Phase 2 | |
Recruiting |
NCT05594576 -
Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy
|
N/A | |
Not yet recruiting |
NCT04135716 -
A Multicenter Study Evaluating the Effectiveness of Endo.Angel in Improving the Quality of Colonoscopy
|
N/A | |
Recruiting |
NCT02552017 -
Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities
|
N/A | |
Completed |
NCT02066064 -
G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist
|
N/A | |
Completed |
NCT01749722 -
Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy
|
N/A | |
Withdrawn |
NCT01546220 -
Water Method in Elder Patients With Unsedated Colonoscopy
|
N/A | |
Completed |
NCT01485133 -
Water Method Colonoscopy in Patients With Prior Surgery
|
N/A | |
Withdrawn |
NCT01546246 -
Water Method in Patients With Incomplete Colonoscopy
|
N/A | |
Withdrawn |
NCT01546259 -
Water Method in Low-body Mass Index (BMI) Female Patients With Unsedated Colonoscopy
|
N/A |